| Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT ...
SEATTLE, Oct. 23 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that the Company has completed enrollment of over 500 patients in the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. The IMPACT study is a double-blind, randomized, placebo-controlled Phase 3 trial designed to measure overall survival in men with metastatic hormone-refractory prostate cancer receiving PROVENGE versus placebo. Earlier this year, following a positive recommendation from an outside panel of experts, Dendreon received a complete response letter from the U.S. Food and Drug Administration (FDA) that asked for additional evidence that would support the efficacy of PROVENGE.
One Reporter’s Opinion — American Education Is Failing Students
It is this reporter's opinion that we Americans must now take a serious look at our educational system. Recently I interviewed Tom DeWeese, president of the American Policy Center and editor of the �The DeWeese Report.� DeWeese is a virtual encyclopedia of information on the subject. He says 20 years ago we ranked first in the world in the number of young adults who earned high school diplomas and college degrees. Today we rank ninth among industrialized nations in the number of young adults who graduate high school and seventh in the number that earn college degrees. We rank 18 out of 24 industrialized nations when it comes to knowledge of history, geography, grammar, civics, and literature. To solve the crisis, politicians, community leaders, and the education community all preach the same mantra.
Antisoma AGM update and Interim Management Statement
"We are making significant advances across our pipeline, and expect to achieve further important milestones during 2008. ASA404 - update on plans for phase III trial in lung cancer Our licensing partner, Novartis, plans to start a pivotal phase III trial of ASA404 in non-small cell lung cancer (NSCLC) in early 2008. This trial will now include patients with both major types of NSCLC: squamous and non-squamous. Previous guidance was that the pivotal study would be limited to patients with squamous disease. Discussions with regulatory authorities regarding the trial design are ongoing. Because more patients are diagnosed with non-squamous than squamous NSCLC, this change more than doubles the population of NSCLC patients addressed directly by the phase III trial. Eligibility for the phase III trial will now be similar to that in our phase II studies, where we showed a substantial survival benefit with ASA404 in a broad population of NSCLC patients.
Broadway actress brings many hues to 'The Color Purple'
I'd been understudying so many parts that they had to hire three people to do what I'd been doing before," she said. 'Thank God for musical theater!' When it opened on Broadway in December, 2005, "The Color Purple" was not a critical favorite. But the musical adaptation of Alice Walker's bestselling novel that spans 40 years in a small Southern African-American community has been an enormous word-of-mouth hit, both in New York and on the road. "The story is so universal that everyone can relate to it," Bayardelle said. "It doesn't matter what color you are, what race, what religion." Although the show has been popular with black audiences in New York, on tour Bayardelle has noticed a more racially heterogeneous audience. Her first experience with "The Color Purple" was watching director Steven Spielberg's 1985 film version.
Photocure announces plans to de-merge PCI Biotech
De-merger will lead to the subsequent listing of PCI Biotech, Photocure's cancer-focused drug delivery subsidiary, on the Oslo Stock Exchange. Oslo, Norway, 16 November 2007 - Photocure ASA (OSE: PHO), a company that develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of different types of cancer, announces that its Board of Directors has decided to a plan to de-merge PCI Biotech, its cancer-focused drug delivery subsidiary. Following the completion of the de-merger process, PCI Biotech intends to seek a public listing on the Oslo Stock Exchange. PCI Biotech has developed a unique method for the light-directed drug delivery of therapeutic molecules directly into tumor cells. This internal delivery of drugs has the potential to enhance the efficacy of current approaches to the treatment of cancer.
Accuray Announces Four New Products at Nation's Leading Radiation ...
SUNNYVALE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Accuray Incorporated (NASDAQ: ARAY) , a global leader in the field of radiosurgery, announced today four new products designed to improve treatment times, optimize treatment planning objectives and offer greater clinical flexibility in radiation delivery. These products are being launched at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Los Angeles. Iris(TM) Variable Aperture Collimator In radiosurgery, clinicians can define the amount, or dose, of radiation delivered during treatment using a collimator -- a metal radiation blocking device with an opening that dictates the shape and size of the radiation beam. In the past, when clinicians wanted to use multiple collimators to vary the size and shape of their radiation beam it required they manually switch out collimators in the middle of treatment.
Manilla loves to love a debutante looking pretty in pink
SEVEN Manilla "ladies" were a vision in pink on the weekend as they donned their finery for the Pink Petal Ball.
The grassroots campaign to raise money for breast cancer research came from months of hard work by a dedicated team who were spurred on by their personal experience with cancer.
The night saw a gaggle of guys dress in drag û to the delight of their audience û to raise thousands of dollars for cancer research.
Four years ago Margaret Clapson lost her daughter Michelle Russell to breast cancer.
Michelle was 32 when she was diagnosed with the illness and died at 36. She left two young children behind. Margaret had already lost a brother in 2000 and another brother in 2001 due to cancer.
Her father and another brother had also suffered with cancer.
Scientists Develop New Drug To Outflank Cancer Resistance, UK
A new drug has shown promising results against breast and prostate cancer cells and tumours that are resistant to conventional hormone-based treatments, according to research published in the British Journal of Cancer.
Cancers such as breast and prostate cancer are often fuelled by sex hormones, such as oestrogen or testosterone. Hormone therapy for breast or prostate cancer aims to reduce the levels of these hormones in the body, "starving" the cancer of these signals and halting tumour growth. Some cancers are resistant to this treatment from the outset while many build up a resistance to these drugs over time, their growth becoming hormone-independent - such cancers are a major challenge to treat.
Now, researchers have shown that a new drug - STX140 - directly targets hormone-independent cancer cells by initiating a natural suicide process within them.
|
